Skye Bioscience, Common Stock Fundamentals
| SKYE Stock | USD 2.86 0.15 4.98% |
Skye Bioscience, Common fundamentals help investors to digest information that contributes to Skye Bioscience,'s financial success or failures. It also enables traders to predict the movement of Skye Stock. The fundamental analysis module provides a way to measure Skye Bioscience,'s intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Skye Bioscience, stock.
At present, Skye Bioscience,'s Interest Income is projected to increase significantly based on the last few years of reporting. Skye | Select Account or Indicator |
Skye Bioscience, Common Company Return On Equity Analysis
Skye Bioscience,'s Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Skye Bioscience, Return On Equity | -0.55 |
Most of Skye Bioscience,'s fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Skye Bioscience, Common is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Skye Other Stockholder Equity
Other Stockholder Equity |
|
Based on the latest financial disclosure, Skye Bioscience, Common has a Return On Equity of -0.5482. This is 97.71% lower than that of the Biotechnology sector and 98.5% lower than that of the Health Care industry. The return on equity for all United States stocks is 76.84% higher than that of the company.
Skye Bioscience, Common Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Skye Bioscience,'s current stock value. Our valuation model uses many indicators to compare Skye Bioscience, value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Skye Bioscience, competition to find correlations between indicators driving Skye Bioscience,'s intrinsic value. More Info.Skye Bioscience, Common is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At present, Skye Bioscience,'s Return On Equity is projected to increase based on the last few years of reporting. Comparative valuation analysis is a catch-all technique that is used if you cannot value Skye Bioscience, by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Skye Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Skye Bioscience,'s direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Skye Bioscience, could also be used in its relative valuation, which is a method of valuing Skye Bioscience, by comparing valuation metrics of similar companies.Skye Bioscience, is currently under evaluation in return on equity category among its peers.
Skye Bioscience, ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Skye Bioscience,'s sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Skye Bioscience,'s managers, analysts, and investors.Environmental | Governance | Social |
Skye Fundamentals
| Return On Equity | -0.55 | ||||
| Return On Asset | -0.3 | ||||
| Current Valuation | 19.55 M | ||||
| Shares Outstanding | 30.34 M | ||||
| Shares Owned By Insiders | 1.89 % | ||||
| Shares Owned By Institutions | 85.41 % | ||||
| Number Of Shares Shorted | 1.59 M | ||||
| Price To Book | 1.14 X | ||||
| EBITDA | (13.55 M) | ||||
| Net Income | (37.64 M) | ||||
| Cash And Equivalents | 2.93 M | ||||
| Cash Per Share | 0.01 X | ||||
| Total Debt | 4.62 M | ||||
| Debt To Equity | 0.84 % | ||||
| Current Ratio | 0.91 X | ||||
| Book Value Per Share | 2.50 X | ||||
| Cash Flow From Operations | (13.95 M) | ||||
| Short Ratio | 5.76 X | ||||
| Earnings Per Share | (3.60) X | ||||
| Target Price | 18.0 | ||||
| Number Of Employees | 11 | ||||
| Beta | 1.75 | ||||
| Market Capitalization | 163.52 M | ||||
| Total Asset | 11.94 M | ||||
| Retained Earnings | (104.38 M) | ||||
| Working Capital | (2.25 M) | ||||
| Net Asset | 11.94 M |
About Skye Bioscience, Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Skye Bioscience, Common's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Skye Bioscience, using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Skye Bioscience, Common based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 1 M | 659.1 K | |
| Cost Of Revenue | 124.3 K | 75.7 K | |
| Sales General And Administrative To Revenue | 0.35 | 0.41 | |
| Capex To Revenue | 0.13 | 0.11 | |
| Revenue Per Share | 8.94 | 9.39 | |
| Ebit Per Revenue | (0.41) | (0.39) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Skye Bioscience, Common is a strong investment it is important to analyze Skye Bioscience,'s competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Skye Bioscience,'s future performance. For an informed investment choice regarding Skye Stock, refer to the following important reports:Check out Skye Bioscience, Piotroski F Score and Skye Bioscience, Altman Z Score analysis. You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Skye Bioscience,. If investors know Skye will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Skye Bioscience, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.60) | Return On Assets (0.30) | Return On Equity (0.55) |
The market value of Skye Bioscience, Common is measured differently than its book value, which is the value of Skye that is recorded on the company's balance sheet. Investors also form their own opinion of Skye Bioscience,'s value that differs from its market value or its book value, called intrinsic value, which is Skye Bioscience,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Skye Bioscience,'s market value can be influenced by many factors that don't directly affect Skye Bioscience,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Skye Bioscience,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Skye Bioscience, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Skye Bioscience,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.